<DOC>
	<DOC>NCT01225939</DOC>
	<brief_summary>A study conducted over 3 periods to look at the drug in the body.</brief_summary>
	<brief_title>A Study Conducted Over 3 Periods to Look at the Drug in the Body</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Provision of signed and dated written informed consent before any study specific procedures including consent for genetic research exploring genetic variations in CYP3A5 suitable veins for cannulation or repeated venepuncture Subjects should have a body mass index (BMI) between 18 and 30 kg/m2 Abnormal vital signs (blood pressure and pulse) after 10 minutes supine rest, as judged by the investigator Prolonged QTcF &gt;450 msec or shortened QTcF &lt;350 msec or family history of long QT syndrome Suspicion of known Gilbert's disease History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Healthy</keyword>
</DOC>